IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
Current SymbolNYSE:IMV
Previous Symbol
CUSIPN/A
WebN/A
Phone(902) 492-1819
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares45,000,000
Market Cap$0.00
OptionableNot Optionable
IMV (NYSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."
How were IMV's earnings last quarter?
Imv Inc (NYSE:IMV) posted its earnings results on Friday, November, 2nd. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.04. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.05 million. View IMV's Earnings History.
When is IMV's next earnings date?
What price target have analysts set for IMV?
2 brokers have issued 1-year target prices for IMV's shares. Their forecasts range from $10.00 to $10.00. On average, they expect IMV's stock price to reach $10.00 in the next year. This suggests a possible upside of 83.5% from the stock's current price. View Analyst Price Targets for IMV.
What is the consensus analysts' recommendation for IMV?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.
Has IMV been receiving favorable news coverage?
News articles about IMV stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IMV earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are some of IMV's key competitors?
Some companies that are related to IMV include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Frederic Ors, CEO, Director & Chief Business Officer
- Pierre Labbé, Chief Financial Officer
- Gabriela Nicola Rosu, Chief Medical Officer
- Marianne Stanford, Vice President-Research
- Joseph Sullivan, Senior Vice President-Business Development
Who are IMV's major shareholders?
IMV's stock is owned by many different of retail and institutional investors. Top institutional investors include FIL Ltd (6.00%), First Manhattan Co. (0.20%), Prentiss Smith & Co. Inc. (0.10%) and Renaissance Technologies LLC (0.06%).
Which institutional investors are selling IMV stock?
IMV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
Which institutional investors are buying IMV stock?
IMV stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co., Prentiss Smith & Co. Inc. and FIL Ltd.
How do I buy shares of IMV?
Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately $5.45.
How can I contact IMV?
The company can be reached via phone at (902) 492-1819.
MarketBeat Community Rating for IMV (NYSE IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
